Calando Pharmaceuticals is a biopharmaceutical company focused on creating targeted therapeutics using its patented and proprietary cyclodextrin-based polymer technologies for the development of nanoparticle drug formulations. Calando’s initial emphasis has been to bring targeted siRNA and small molecule therapeutics to the clinic for oncology applications; however, the technologies are not limited to these classes of molecules and are applicable to a very broad range of therapeutic entities and diseases.
The Calando technology for RNAi, called RONDEL™, overcomes the significant hurdles to efficient, systemic delivery of siRNA. Calando’s technology for siRNA therapeutics:
- Allows for repeat dosing without the risk of immune reactions
- Has demonstrated efficient, targeted delivery in animal models
- Has overcome the extra- and intra-cellular barriers to siRNA delivery
- Has been scaled-up and manufactured for clinical use
In addition to the RNAi technologies and pipeline, Calando Pharmaceuticals has developed a technology that involves small molecule drugs. This technology, called Cyclosert™, leads to designed nanoparticle therapeutics that:
- Greatly enhance solublization of low solubility molecules
- Provide for long circulation in humans (half life of ca. 40 hours) by designed modulation of absorption, distribution, metabolism and excretion
- Target specific disease tissues
- Have controlled and tunable drug release profiles to match mechanism of action
In June of 2009 Calando Pharmaceuticals has entered into a worldwide license agreement with Cerulean Pharma Inc. for Calando's drug delivery platform, Cyclosert™, and associated clinical stage anti-cancer drug, IT-101.
In addition to focusing on its therapeutic pipeline, Calando’s patented and proprietary delivery systems have utility in application areas not internally pursued by Calando. Consequently, we are continually exploring additional opportunities to combine our delivery systems with companies seeking delivery solutions. |
